SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
Document › Details

PX’Therapeutics S.A.. (10/1/12). "Press Release: Aguettant, an Independent French Pharmaceutical Company, and PX'Therapeutics, a French Contract Manufacturing Organization Dedicated to the Development of Recombinant Proteins, Join Forces to Boost Their A

Region Region France
Organisations Organisation PX’Therapeutics S.A.
  Group Aguettant (Group)
  Organisation 2 Aguettant Biotech
  Group Aguettant (Group)
Products Product contract manufacturing (biologicals)
  Product 2 pharmaceutical
Index term Index term PX'Therapeutics–Aguettant: investment, 201210 acquisition of majority stake by Aguettant Biotech
Persons Person Rousselle, Tristan (Protein’eXpert 200011–201306 CEO + Co-Founder LEFT 6/13 before Genome Express)
  Person 2 Mouz, Nicolas (PX'Therapeutics 201008– CEO of Promise Advanced Proteomics)

Aguettant, a pioneer in drugs for injection since 1903, invests in the field of biotechnologies. Aguettant Biotech, a fully-owned subsidiary of Aguettant Santé, acquires a majority stake in the equity of PX'Therapeutics.

PX'Therapeutics, a specialist in protein engineering and development of protein and antibody
therapeutics from the early research stage through to the preclinical and clinical phase I/II production, will benefit greatly from joining Aguettant group. The company will expand and further strengthen its services to customers by increasing its manufacturing capabilities to industrial scale, to support latestage clinical studies and commercial scale production.

Through this operation, Aguettant creates a capability to develop biotechnology products in the future, alone or in partnership with other companies.

PX'Therapeutics will remain autonomous in its business and fully dedicated to customers' projects. PX'Therapeutics co-founders, Tristan Rousselle and Nicolas Mouz, will stay as minority shareholders.

The company's management remains under the direction of Tristan Rousselle.


o Family-owned pharmaceutical company based in Lyon, France
o Sales over € 85 M over the past 12 months, of which more than 20% abroad
o 3 development axis:
o designing and industrialising innovative drug delivery systems for enhanced security in emergency medicine,
o offering a range of essential micro-nutrients capable of preventing and curing critical deficiencies,
o taking care of patients suffering from severe symptoms of Parkinson's disease.
o Main project in progress: building a new R&D and manufacturing unit with the prospect of boosting innovation capabilities and enhancing international growth.


o Based in Grenoble and in Lyon, France
o Established in 2000
o Over 50 employees
o Turnover : € 4 M + € 4.5 M of other revenues (2011)
o 190 clients - 60% of the turnover is generated from customers outside France
o Over 800 recombinant protein and monoclonal antibodies projects performed so far - several clinical batches produced are currently in phase I and II clinical trials in Europe and the USA.


Coralie Mannino
Phone : +33 4 78 61 47 69
Fax : +33 4 78 61 09 35
Email :

Claire Untereiner
Phone : +33 4 38 02 36 59
Fax : +33 4 76 96 10 38
Email :

Record changed: 2016-01-10


Picture [LSE] – The Business Web Portal 600x60px

More documents for Aguettant (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [LSUS] – The Business Web Portal 600x60px

» top